Land: Den Europæiske Union
Sprog: engelsk
Kilde: EMA (European Medicines Agency)
nelarabine
Sandoz Pharmaceuticals d.d.
L01BB07
nelarabine
Antineoplastic agents
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Nelarabine is indicated for the treatment of patients with T-cell acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. Due to the small patient populations in these disease settings, the information to support these indications is based on limited data.,
Revision: 26
Authorised
2007-08-22
23 B. PACKAGE LEAFLET 24 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT ATRIANCE 5 MG/ML SOLUTION FOR INFUSION nelarabine This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects. READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET : 1. What Atriance is and what it is used for 2. What you need to know before you are given Atriance 3. How Atriance is given 4. Possible side effects 5. How to store Atriance 6. Contents of the pack and other information 1. WHAT ATRIANCE IS AND WHAT IT IS USED FOR Atriance contains nelarabine which belongs to a group of medicines known as _antineoplastic agents,_ used in chemotherapy to kill some types of cancer cells. ATRIANCE IS USED TO TREAT PATIENTS WITH: • a type of leukaemia, called T-cell acute lymphoblastic leukaemia. Leukaemia causes an abnormal increase in the number of white blood cells. The abnormal high number of white blood cells can appear in the blood and other parts of the body. The type of leukaemia relates to the type of white blood cell mainly involved. In this case, its cells are called lymphoblasts. • a type of lymphoma, called T-cell lymphoblastic lymphoma. This lymphoma is caused by a mass of lymphoblasts, a type of white blood cell. If you have any questions about your illness, talk to your doctor 2. WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN ATRIANCE YOU (OR YOUR CHILD, IF HE/SHE IS BE Læs hele dokumentet
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Atriance 5 mg/ml solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of solution contains 5 mg of nelarabine. Each vial contains 250 mg of nelarabine. Excipient with known effect Each ml of solution contains 1.770 mg (77 micromols) of sodium. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for infusion. Clear, colourless solution. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Nelarabine is indicated for the treatment of patients with T-cell acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. Due to the small patient populations in these disease settings, the information to support these indications is based on limited data. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Nelarabine must only be administered under the supervision of a physician experienced in the use of cytotoxic agents. Posology Complete blood counts including platelets must be monitored regularly (see sections 4.4 and 4.8). _Adults and adolescents (aged 16 years and older) _ The recommended dose of nelarabine for adults and adolescents aged 16 years and older is 1,500 mg/m 2 administered intravenously over two hours on days 1, 3 and 5 and repeated every 21 days. _Children and adolescents (aged 21 y_ _ears and younger) _ The recommended dose of nelarabine for children and adolescents (aged 21 years and younger) is 650 mg/m 2 administered intravenously over one hour daily for 5 consecutive days, repeated every 3 21 days. In clinical studies, the 650 mg/m 2 and 1,500 mg/m 2 dose have both been used in patients in the age range Læs hele dokumentet